Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Nokia Corp (NOK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Nokia Corp — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.77 (market cap $4.49B), while Nokia Corp trades at $11.77 (market cap $66.24B). The key difference: Nokia Corp is far larger — about 14.8× ACADIA Pharmaceuticals Inc.'s market cap, and Nokia Corp pays a 1.38% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | NOK | |
|---|---|---|
Market Cap | $4.49B | $66.24B |
Sector | Health | Technology |
52-Week High | $28.06 | $16.83 |
52-Week Low | $20.06 | $4.05 |
Enterprise Value | $3.69B | $63.06B |
Dividend Yield | — | 1.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Nokia (NOK) trades at $11.85, down 1.74% amid a bearish technical signal, despite strong year-to-date performance. The company shows mixed fundamentals with a high P/E of 78.47 but recent earnings beats and a 44.12% gross margin. Recent news highlights Nokia's strategic pivot to AI infrastructure, including partnerships with Nvidia and Amazon Web Services, driving investor optimism about future growth potential in network modernization and data center markets.
Outlook remains cautiously optimistic with a consensus price target of $18.00 representing 52% upside, though high valuation and recent earnings miss pose risks. The stock's direction hinges on execution of AI initiatives and Q2 2026 earnings results due July 23, with technical indicators suggesting near-term consolidation near current support levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Nokia Corp
Nokia is a leading vendor in the telecommunications equipment industry. The company's network business derives revenue from selling wireless and fixed-line hardware, software, and services. Nokia's technology segment licenses its patent portfolio to handset manufacturers and makes royalties from Nokia-branded cellphones. The company, headquartered in Espoo, Finland, operates on a global scale, with most of its revenue from communication service providers.
Read more on NOK →
